Plain-English translation of NCT05039801 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called IACS-6274 designed to help fight advanced cancers that have stopped responding to standard treatments. You would receive the medication by mouth, either on its own or combined with one or two other cancer drugs, depending on which group you join. Doctors will watch closely to find the right dose and learn how well this treatment works.
Many patients with advanced cancers run out of effective treatment options when their tumors stop responding to standard therapies. This medication targets a specific pathway in cancer cells, and this trial is exploring whether it can offer a new hope for patients who have limited options left.
You likely qualify if…
You likely don't qualify if…
You will visit the cancer center regularly for check-ins, blood tests, and scans to monitor your health and how your cancer responds. Depending on which group you join, you will either take the medication by mouth daily alone, or take it combined with other intravenous or oral medications. The trial will track your side effects carefully and may adjust your dose to find what works best and is safest for you.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States